Literature DB >> 3249784

Abnormal Involuntary Movement Scale (AIMS).

.   

Abstract

Entities:  

Mesh：

Year:  1988        PMID： 3249784

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN： 0048-5764


× No keyword cloud information.
  6 in total

1.  A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Authors:  T Scott Stroup; Joseph P McEvoy; Kimberly D Ring; Robert H Hamer; Lisa M LaVange; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Abraham M Nussbaum; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2011-07-18       Impact factor: 18.112

2.  Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study.

Authors:  S G Potkin; J A Turner; G G Brown; G McCarthy; D N Greve; G H Glover; D S Manoach; A Belger; M Diaz; C G Wible; J M Ford; D H Mathalon; R Gollub; J Lauriello; D O'Leary; T G M van Erp; A W Toga; A Preda; K O Lim
Journal:  Schizophr Bull       Date:  2008-11-27       Impact factor: 9.306

3.  Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age.

Authors:  J Kulkarni; E Gavrilidis; W Wang; R Worsley; P B Fitzgerald; C Gurvich; T Van Rheenen; M Berk; H Burger
Journal:  Mol Psychiatry       Date:  2014-04-15       Impact factor: 15.992

Review 4.  Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.

Authors:  Henk S Temmingh; Taryn Williams; Nandi Siegfried; Dan J Stein
Journal:  Cochrane Database Syst Rev       Date:  2018-01-22

5.  Smoking status as a potential confounder in the study of brain structure in schizophrenia.

Authors:  Claudia E Schneider; Tonya White; Johanna Hass; Daniel Geisler; Stuart R Wallace; Veit Roessner; Daphne J Holt; Vince D Calhoun; Randy L Gollub; Stefan Ehrlich
Journal:  J Psychiatr Res       Date:  2013-12-18       Impact factor: 4.791

6.  Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation.

Authors:  Theo G M van Erp; Ilaria Guella; Marquis P Vawter; Jessica Turner; Gregory G Brown; Gregory McCarthy; Douglas N Greve; Gary H Glover; Vince D Calhoun; Kelvin O Lim; Juan R Bustillo; Aysenil Belger; Judith M Ford; Daniel H Mathalon; Michele Diaz; Adrian Preda; Dana Nguyen; Fabio Macciardi; Steven G Potkin
Journal:  Biol Psychiatry       Date:  2013-08-01       Impact factor: 13.382
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.